Futura Medical Share Price (FUM)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Futura Medical	LSE:FUM	London	Ordinary Share	GB0033278473	ORD 0.2P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	-1.50p	-3.03%	48.00p	47.00p	49.00p	49.50p	47.50p	49.50p	129,818	16:13:30

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.2	-4.5	-3.7	-	57.92

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Valirx (VAL), Port Erin (PEBI)

Futura Medical (FUM) Latest News

Futura Medical News

Date	Time	Source	Headline
04/7/2017	07:00	UKREG	Futura Medical PLC Investor Presentation on MED2002
14/6/2017	17:00	UKREG	Futura Medical PLC Result of AGM
14/6/2017	10:42	ALNC	Futura Medical Focus On Sexual Health Products In 2017
14/6/2017	07:40	ALNCF	Alliance News Flash Headline
14/6/2017	07:00	UKREG	Futura Medical PLC AGM Statement
31/5/2017	11:38	ALNC	Futura Medical Gets Clear Regulatory Path For Erectile Dysfunction Gel
31/5/2017	07:00	UKREG	Futura Medical PLC Total Voting Rights
31/5/2017	07:00	UKREG	Futura Medical PLC MED2002 Regulatory Update
22/5/2017	07:01	UKREG	Futura Medical PLC Block Listing Update
20/4/2017	09:45	UKREG	Futura Medical PLC Notice of AGM

More Futura Medical News

Futura Medical Takeover Rumours

Futura Medical (FUM) Share Charts

1 Year Futura Medical Chart

1 Month Futura Medical Chart

Intraday Futura Medical Chart

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date	Time	Title	Posts
18/8/2017	15:04	FUTURA a winner for 2015	2,992
08/5/2017	10:53	www.bluediamondcondom.com	50
02/12/2016	13:27	FUM delivering on sex,pain and rock'n'roll	11,414
21/6/2016	08:43	fum reality	1
07/11/2014	12:19	fum	-

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2017-08-18 15:29:47	48.80	2,000	976.00	O
2017-08-18 15:29:15	48.80	2,028	989.66	O
2017-08-18 15:13:39	48.00	10,000	4,800.00	O
2017-08-18 14:47:45	48.00	1,045	501.60	O
2017-08-18 14:46:49	47.20	1,137	536.66	O

View all Futura Medical trades in real-time

Futura Medical (FUM) Top Chat Posts

Date	Subject
18/8/2017 09:20	Futura Medical Daily Update: Futura Medical is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 49.50p. Futura Medical has a 4 week average price of 47.50p and a 12 week average price of 47.50p. The 1 year high share price is 96.25p while the 1 year low share price is currently 21p. There are currently 120,658,682 shares in issue and the average daily traded volume is 114,063 shares. The market capitalisation of Futura Medical is £57,916,167.36. Read Full Thread Reply
04/7/2017 11:44	jamesd888: Great presentation look at the Ipsos US Forecast on slide 31...users, tubes and dollars....in five years time the share price could easily be 4.00-5.00+ based on this....so i see why big institutions and investors would buy into FUM now Read Full Thread Follow Reply
14/6/2017 10:18	jamesd888: qruz... what share price would someone have to pay for a takeover bid for FUM in your opinion? Read Full Thread Follow Reply
07/6/2017 09:33	mikethebike4: james 'There will also be many new launches of the condom within the next 6 months which will help with the profile and see FUM Share price rocket....so the next 6 months are most interesting and the best time to be in here. - I have seen this written so many times over the last few years - I will be so shocked when it actually happens I will probably climax on the spot without the aid of Blue Diamond ! - 18 months product is already available from TTK in Asia - why they did not submit for regulatory approval at the same time in Europe I do not know - however I am expecting an announcement by the BoD so that the AGM is not a 'damp squib' MTB4 Read Full Thread Follow Reply
06/6/2017 22:59	jamesd888: There will also be many new launches of the condom within the next 6 months which will help with the profile and see FUM Share price rocket....so the next 6 months are most interesting and the best time to be in here. Read Full Thread Follow Reply
27/3/2017 11:41	loobrush: from iii What is the future for Futura's share price. I have detailed below, from info in the results and more particularly from the webcast presentation (which not many may have seen-but now available on their website) what news Futura expects to announce during 2017, of which there is quite a lot. MED2000-Securing of major commercial deal. CSD500-Church & Dwight launch in selected markets(probably UK, France & Germany ) CSD500-Launch in 6 more countries and possibly up to 13. TPR100 & TIB200 -securing of further deals in USA/Europe. So what about the share price. Clearly there is massive potential if all the products end up all on sale at once but leading up to that point I think that announcements of each of the above this year will increase the share price as each one will confirm that progress is being made, some more than others. Clearly with any deal being announced one can expect upfront deal fees which can be substantial and this is what Futura expect as they stated at the results seminar they have no need to raise further cash. Looking at other company deals in these sectors the total upfront fees could easily be in the £25-40 million range. So what could Futura be worth in a couple of years time. From global sales figures provided by Futura we have the following peak potential for Futura's market share and earnings. MED 2000 ($1 billion per annum)= £800 million say @5% royalty is £40 million pa TPR100 & TIB200 (1/2 billion per annum)=£400 million say @5% royalty is £20 million pa CSD500 @10% market share of a $6billion pa market is $600 million=£450 million @ 5% royalty rate is £9 million per annum. That totals to £69 million per annum. That's the peak potential. Lets discount that by 1/2 that gives £34.5 million per annum. So with an income of that size with minimal overheads the company on a p/e of 8 would be valued at £552 million or 460p per share Current company value@53p is £63million So the potential is 9 times the current share price. With lots of news this year we could easily see the share price double up with the newsflow and big bucks coming after the MED 2000 trial results in a year or so. Price may drift a bit before the first news but as news may come at any time so it's a hold or buy at this price in my view. Also there may be a surprise announcement of a new product(s) as they are working on this at the moment. Read Full Thread Follow Reply
21/3/2017 13:59	bull sykes: From FUM Interim Results published 13.09.2016. Bottom of Page 3 - "Commercial manufacture of product for the launch of CSD500 in the first Middle East country, where regulatory approval has already been granted, has already taken place with the launch expected later this year. The initial royalty payment has already been received for this and will be recognised upon launch. We anticipate further launches of the product in other territories during 2017." End Quote. CSD500 recently launched in Saudi-Arabia, so I am assume 'recognised upon launch' to mean that royalty payments will be visible in the accounts. Hopefully there will be info about amount of initial sales. 1) It will show the market FUM has a royalties income stream for the first time. 2) It might prompt the business press to articulate more often on FUM progress, and help to stabilise /improve the share price. I posted the above on another board recently. It just remains for the market to be satisfied with the numbers.. Read Full Thread Follow Reply
07/2/2017 16:07	sportbilly1976: Further to my post earlier, I rang FUM. Message taken and I've just had a call back. Essentially all is okay with progress on multiple fronts (commercialisation deals etc)but they are disappointed with the recent share price fall Understand that the fall in share price recently nothing more than retail selling pressure. They are currently looking to build the institutional shareholder base. Two announcements this year not had the impact they might have hoped, but down to the vagaries of the market. It was also mentioned that the LSE have contacted the Company over the fall, but nothing material & undisclosed behind the fall Lack of "we know of no reason..." rns - essentially striking a balance between allowing the market to function and appearing defensive with any announcement to reassure shareholders On the back of the call I am reassured to continue to hold and will look to add when funds allow at these levels Read Full Thread Follow Reply
04/1/2017 08:50	greedfear: Yes, good deals take time. People investing in these kind of ventures should know that expectations are just that, expectations. Patience is often needed (sometimes having trouble there myself) but the wait is often worth it. I'm very confident the share price will increase >100% this year. Just too much going on. Also I believe FUM to be a take over target for big pharma at a price that would be multiples of the current share price. Read Full Thread Follow Reply
16/11/2016 12:37	loobrush: Med2002 has the potential for a double whammy with over the counter(OTC) for low dose and prescription only for the high dose.I don't know which will be biggest,but it seems to me that the OTC version could be miles bigger as people will try this whether they have a problem or not.If the OTC version was put on sale now a lot of men would try it just to see what happens let alone those with a problem who dont want to see a doctor.FUM'S value is certainly higher than todays share price and my own valuation if the final trial goes well is that the share price will be over £3.00 by this time next year. Next we should hear first launch news on CSD500 before Xmas and European manufacturing approval-then into next year further launches across the globe-so plenty of news coming to and as things progress share price will move up accordingly. Read Full Thread Follow Reply
13/11/2013 09:39	sceptic bull: Looking to get back into the small cap markets and I like the look of FUM as one of many many candidates to invest. Attractions: The product will sell itself regardless of marketing ability of partner with plenty of mainstream media coverage. Low cost base of Company therefore any funding will not be significant. If the product works as described then it will get a good % of the market The IP. The main players would have tried very hard to produce their own in-house OTC product but clearly they haven't been able to. Eddison's market share projections and target share price look conservative. Question marks Trial was quite limited. 100 participants. Why no follow up trial to assist marketing claims? How conclusive was the trial? I doubt if this is a big issue but a further conclusive trial would have given me more confidence. If this product works then FUM will get a very significant share of the market. Why did RB relinquish? Not especially important as big companies can make silly decisions. Drop in share price. Are FUM doing a placing? Markets for funding small caps usually exact a discount. Although if reason for drop is some placing leak then I doubt it has further to fall. Despite being in control of production issues FUM cannot control launch date for CSD Limited progress on pain relief products so FUM share price is very reliant on CSD500 Any potential competition. Unlikely as there has been plenty of time to produce something. How good is the board of directors and especially the CEO? Seems competent but not over inspiring. Read Full Thread Follow Reply

Futura Medical share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:40 V: D:20170819 07:12:07